Evidence map›Paper›PMID 34040950›Full record

ArticleGlobal heart2021

Cost-Effectiveness of Improved Hypertension Management in India through Increased Treatment Coverage and Adherence: A Mathematical Modeling Study.

Hemanshu Das, Andrew E Moran, Anupam K Pathni, Bhawna Sharma, Abhishek Kunwar, Sarang Deo

Open access · goldAbstract read
In one paragraph

Article in Global heart, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Blood pressure targets for hypertension in people with diabetes mellitus.The Cochrane database of systematic reviews · 2026
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Hemanshu DasIndian School of Business, Hyderabad, IN.ORCID 0000-0002-0179-7491
Andrew E MoranResolve to Save Lives, an initiative of Vital Strategies, New York, US.ORCID 0000-0003-3554-0085
Anupam K PathniResolve to Save Lives, an initiative of Vital Strategies, New York, US.ORCID 0000-0001-7582-0861
Bhawna SharmaResolve to Save Lives, an initiative of Vital Strategies, New York, US.ORCID 0000-0002-3563-7453
Abhishek KunwarWorld Health Organization Country Office for India, New Delhi, IN.ORCID 0000-0003-1281-1487
Sarang DeoIndian School of Business, Hyderabad, IN.ORCID 0000-0002-3233-6014
Vital Strategies · USIndian School of Business · INWorld Health Organization - India · IN

Funding

World Health Organization 001
6 · The paper itself

Abstract

Background: Despite the availability of effective and affordable treatments, only 14% of hypertensive Indians have controlled blood pressure. Increased hypertension treatment coverage (the proportion of individuals initiated on treatment) and adherence (proportion of patients taking medicines as recommended) promise population health gains. However, governments and other payers will not invest in a large-scale hypertension control program unless it is both affordable and effective. Objective: To investigate if a national hypertension control intervention implemented across the private and public sector facilities in India could save overall costs of CVD prevention and treatment. Methods: We developed a discrete-time microsimulation model to assess the cost-effectiveness of population-level hypertension control intervention in India for combinations of treatment coverage and adherence targets. Input clinical parameters specific to India were obtained from large-scale surveys such as the Global Burden of Disease as well as local clinical trials. Input hypertensive medication cost parameters were based on government contracts. The model projected antihypertensive treatment costs, avoided CVD care costs, changes in disability-adjusted life year (DALYs) and incremental cost per DALY averted (represented as incremental cost-effectiveness ratio or ICER) over 20 years. Results: Over 20 years, at 70% coverage and adherence, the hypertension control intervention would avert 1.68% DALYs and be cost-saving overall. Increasing adherence (while keeping coverage constant) resulted in greater improvement in cost savings compared to increasing coverage (while keeping adherence constant). Results were most sensitive to the cost of antihypertensive medication, but the intervention remained highly cost-effective under all one-way sensitivity analyses. Conclusion: A national hypertension control intervention in India would most likely be budget neutral or cost-saving if the intervention can achieve and maintain high levels of both treatment coverage and adherence.

Indexed as

HypertensionAntihypertensive AgentsCost-Benefit AnalysisHumansIndiaQuality-Adjusted Life YearsAntihypertensive Agentscost-effectivenessdeveloping countrieshealth policyhypertensionpreventive care

Identifiers

PMID34040950
PMCPMC8121007
OpenAlexW3162235779

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.